Scienture

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Aug 25, 2025FDANarcan — KLOXXADO

Apr 19, 2024FDANarcan — REZENOPY

Jul 28, 2023FDANarcan — RIVIVE

Mar 7, 2023FDANarcan — REXTOVY

Feb 28, 2022FDANarcan — NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

Oct 15, 2021FDANarcan — ZIMHI

Jan 24, 2017FDANarcan — NARCAN

Oct 19, 2016FDANarcan — EVZIO (AUTOINJECTOR)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

10 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Narcan4 patentsFeb 1, 2026 Narcan3 patentsFeb 20, 2027 Narcan2 patentsMar 12, 2028 Narcan2 patentsApr 10, 2029 Narcan7 patentsFeb 28, 2031 Narcan4 patentsFeb 4, 2032 Narcan8 patentsJul 18, 2034 NarcanMar 20, 2035

2 more

NarcanMay 24, 2039 Narcan3 patentsFeb 5, 2041

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Narcan — NARCAN

Application NDA016636 (NDA)

20141 event

FDAApr 3

Narcan — EVZIO

Application NDA205787 (NDA)

20161 event

FDAOct 19

Narcan — EVZIO (AUTOINJECTOR)

Application NDA209862 (NDA)

20171 event

FDAJan 24

Narcan — NARCAN

Application NDA208411 (NDA)

20211 event

FDAOct 15

Narcan — ZIMHI

Application NDA212854 (NDA)

20221 event

FDAFeb 28

Narcan — NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

Application NDA215457 (NDA)

20232 events

FDAJul 28

Narcan — RIVIVE

Application NDA217722 (NDA)

FDAMar 7

Narcan — REXTOVY

Application NDA208969 (NDA)

20241 event

FDAApr 19

Narcan — REZENOPY

Application NDA215487 (NDA)

20251 event

FDAAug 25

Narcan — KLOXXADO

Application NDA212045 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)